TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07226986: A Phase Ib/II Open-label, Multi-center Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With an Androgen Receptor Pathway Inhibitor (ARPI) in Adult Participants With PSMA-positive Metas

Sponsor: Novartis Pharmaceuticals · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 123 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$8,443,050

Rescue Site Savings

+$5,576,340

Unlock Full NCT07226986 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07226986 Rescue Dossier →